New Collaboration to Expand Access to Biologic Medicines
SYDNEY — Samsung Bioepis has announced a new partnership with Sandoz for the development and commercialization of up to five biosimilar candidates, including SB36, a biosimilar referencing Entyvio (vedolizumab). The agreement excludes territories such as China and South Korea, according to a statement released today.
Background on the Biosimilar Market
The announcement builds on a previous collaboration between the companies, including agreements for biosimilars PYZCHIVA and EPYSQLI. The biosimilar market continues to grow, driven by increasing demand for affordable biologic therapies, and this partnership represents another step towards broader access.
Biosimilars play a crucial role in the healthcare industry by providing more cost-effective alternatives to expensive biologic medicines. As patents for original biologic drugs expire, the opportunity for biosimilar development expands, allowing more patients to benefit from these treatments. This collaboration between Samsung Bioepis and Sandoz is expected to enhance competition and drive down the costs of biologics, benefiting healthcare systems worldwide.
The partnership aims to address the increasing global healthcare challenges by ensuring that high-quality biosimilars are available to a broader patient population. This effort is particularly important in regions where access to biologic medicines is limited due to high costs. By leveraging Sandoz’s extensive commercialization capabilities and Samsung Bioepis’s expertise in biosimilar development, the two companies are well-positioned to make a significant impact on the market.
This partnership not only strengthens the relationship between Samsung Bioepis and Sandoz but also marks a significant milestone in the ongoing effort to improve patient access to essential biologic therapies. As the biosimilar market continues to evolve, collaborations like this will be crucial in ensuring that patients worldwide have access to affordable and effective treatments.
Source: newshub.medianet.com.au
Last updated: 2 April 2026, 4:34 pm
